MADRIGAL PHARMACEUTICALS INC (MDGL) Stock Price & Overview
NASDAQ:MDGL • US5588681057
Current stock price
The current stock price of MDGL is 454.22 USD. Today MDGL is up by 2.76%. In the past month the price increased by 3.97%. In the past year, price increased by 32.96%.
MDGL Key Statistics
- Market Cap
- 10.42B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -12.75
- Dividend Yield
- N/A
MDGL Stock Performance
MDGL Stock Chart
MDGL Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MDGL. When comparing the yearly performance of all stocks, MDGL turns out to be only a medium performer in the overall market: it outperformed 59.05% of all stocks.
MDGL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MDGL. The financial health of MDGL is average, but there are quite some concerns on its profitability.
MDGL Earnings
On February 19, 2026 MDGL reported an EPS of -2.57 and a revenue of 321.08M. The company missed EPS expectations (-274% surprise) and beat revenue expectations (0.74% surprise).
MDGL Forecast & Estimates
23 analysts have analysed MDGL and the average price target is 671.77 USD. This implies a price increase of 47.9% is expected in the next year compared to the current price of 454.22.
For the next year, analysts expect an EPS growth of 62.32% and a revenue growth 57.04% for MDGL
MDGL Groups
Sector & Classification
MDGL Financial Highlights
Over the last trailing twelve months MDGL reported a non-GAAP Earnings per Share(EPS) of -12.75. The EPS increased by 42.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.89% | ||
| ROE | -47.83% | ||
| Debt/Equity | 0.56 |
MDGL Ownership
MDGL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.9 | 368.381B | ||
| AMGN | AMGEN INC | 15.33 | 189.472B | ||
| GILD | GILEAD SCIENCES INC | 15.96 | 175.4B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.63 | 114.717B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.77 | 78.668B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.7 | 41.749B | ||
| INSM | INSMED INC | N/A | 30.759B | ||
| NTRA | NATERA INC | N/A | 28.033B | ||
| BIIB | BIOGEN INC | 11.41 | 26.756B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.64 | 23.245B | ||
| MRNA | MODERNA INC | N/A | 20.695B | ||
| EXAS | EXACT SCIENCES CORP | 341.89 | 19.805B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.443B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MDGL
Company Profile
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 915 full-time employees. The company went IPO on 2007-02-06. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Company Info
IPO: 2007-02-06
MADRIGAL PHARMACEUTICALS INC
200 Barr Harbor Drive, Suite 400
West Conshohocken PENNSYLVANIA 19428 US
CEO: Paul A. Friedman
Employees: 528
Phone: 14043809263
MADRIGAL PHARMACEUTICALS INC / MDGL FAQ
What does MADRIGAL PHARMACEUTICALS INC do?
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 915 full-time employees. The company went IPO on 2007-02-06. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
What is the current price of MDGL stock?
The current stock price of MDGL is 454.22 USD. The price increased by 2.76% in the last trading session.
What is the dividend status of MADRIGAL PHARMACEUTICALS INC?
MDGL does not pay a dividend.
What is the ChartMill technical and fundamental rating of MDGL stock?
MDGL has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of MADRIGAL PHARMACEUTICALS INC (MDGL)?
MADRIGAL PHARMACEUTICALS INC (MDGL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.75).
When does MADRIGAL PHARMACEUTICALS INC (MDGL) report earnings?
MADRIGAL PHARMACEUTICALS INC (MDGL) will report earnings on 2026-04-29, before the market open.
Can you provide the short interest for MDGL stock?
The outstanding short interest for MADRIGAL PHARMACEUTICALS INC (MDGL) is 17.71% of its float.